Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEAYA Biosciences, Inc.IDYA · Entity 4069 | Chief Accounting Officer | July 07, 2026 | July 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEAYA Biosciences, Inc.
Report date July 07, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,466 |
Ending reported balance
After 2026-07-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-07 · Exercise / conversion · Acquired 9,550 · Balance 36,016 Row 2 · 2026-07-07 · Sale · Disposed 9,550 · Balance 26,466 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 19, 2025. F2: This transaction was executed in multiple trades in prices ranging from $40.00 to $40.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.86 · Expires 2032-03-01 | Direct | 19,200 |
Reported balance
After 2026-07-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-07 · Exercise / conversion · Disposed 9,550 · Balance 19,200 F3: 100% of the shares subject to the option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 19, 2025.
F2: This transaction was executed in multiple trades in prices ranging from $40.00 to $40.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: 100% of the shares subject to the option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 07, 2026 Filed Jul 9, 2026 20:56 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,550 | $0.00 Strike: $12.86 | $0.00 |
DisclosureSEC source: 0001610717-26-000336 · form4.xml · derivative · entry 3 Ruiz Briseno Andres · CIK 0001983118 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,200 Underlying: Common Stock · 9,550 shares Expires 2032-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 100% of the shares subject to the option is fully vested and exercisable. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 20:56 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 9,550 | $40.01 | $382,130.84 |
DisclosureSEC source: 0001610717-26-000336 · form4.xml · nonDerivative · entry 2 Ruiz Briseno Andres · CIK 0001983118 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,466 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 19, 2025. F2 · price: This transaction was executed in multiple trades in prices ranging from $40.00 to $40.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 20:56 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 9,550 | $12.86 | $122,813.00 |
DisclosureSEC source: 0001610717-26-000336 · form4.xml · nonDerivative · entry 1 Ruiz Briseno Andres · CIK 0001983118 · Chief Accounting Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 00:55 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $32.19 | $0.00 |
DisclosureSEC source: 0001610717-26-000032 · form4.xml · derivative · entry 3 Ruiz Briseno Andres · CIK 0001983118 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2036-01-30 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| November 28, 2025 Filed Feb 3, 2026 00:55 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantCommon Stock | 1,253 | $16.91 | $21,183.84 |
DisclosureSEC source: 0001610717-26-000032 · form4.xml · nonDerivative · entry 2 Ruiz Briseno Andres · CIK 0001983118 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,466 F1 · kind: The shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 23:02 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $20.24 | $0.00 |
DisclosureSEC source: 0001610717-25-000041 · form4.xml · derivative · entry 1 Ruiz Briseno Andres · CIK 0001983118 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2035-02-26 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| November 29, 2024 Filed Feb 3, 2026 00:55 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantCommon Stock | 682 | $23.26 | $15,860.59 |
DisclosureSEC source: 0001610717-26-000032 · form4.xml · nonDerivative · entry 1 Ruiz Briseno Andres · CIK 0001983118 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,213 F1 · kind: The shares were acquired under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 22:27 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $46.22 | $0.00 |
DisclosureSEC source: 0001610717-24-000119 · form4.xml · derivative · entry 1 Ruiz Briseno Andres · CIK 0001983118 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 21:59 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 2,000 | $46.02 | $92,044.60 |
DisclosureSEC source: 0001610717-24-000059 · form4.xml · nonDerivative · entry 1 Ruiz Briseno Andres · CIK 0001983118 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,531 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 30, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $46.00 to $46.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 22, 2024 Filed Jan 25, 2024 00:12 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 2,000 | $42.03 | $84,050.20 |
DisclosureSEC source: 0001610717-24-000041 · form4.xml · nonDerivative · entry 1 Ruiz Briseno Andres · CIK 0001983118 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,531 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 30, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $42.00 to $42.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 12, 2024 Filed Jan 17, 2024 22:41 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 2,000 | $38.01 | $76,025.60 |
DisclosureSEC source: 0001610717-24-000029 · form4.xml · nonDerivative · entry 1 Ruiz Briseno Andres · CIK 0001983118 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,531 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 30, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $38.00 to $38.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 22:45 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 328 | $34.01 | $11,153.64 |
DisclosureSEC source: 0001610717-23-000403 · form4.xml · nonDerivative · entry 2 Ruiz Briseno Andres · CIK 0001983118 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,531 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 30, 2023. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 22:45 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 1,672 | $34.00 | $56,848.00 |
DisclosureSEC source: 0001610717-23-000403 · form4.xml · nonDerivative · entry 1 Ruiz Briseno Andres · CIK 0001983118 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,859 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 30, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 22:36 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 2,000 | $30.01 | $60,016.00 |
DisclosureSEC source: 0001610717-23-000257 · form4.xml · nonDerivative · entry 1 Ruiz Briseno Andres · CIK 0001983118 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,531 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 30, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $30.00 to $30.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.